Biocure Technology (CSE:CURE, OTCQB:BICTF)
Biocure Technology (CSE:CURE, OTCQB:BICTF)
Biotechnology research
Sector
Front runner in CAR-T cell therapy for cancer patients

Business Highlights

Biocure Pharma is a leading biotech company developing its CAR-T cell therapy for leukemia, lung, breast and pancreatic cancer. Headquartered in Korea, Biocure Pharma has joint venture partners in Asia and Europe with planned clinical trials commencing in 2021. Biocure is listed on both the Canadian Stock Exchange and OTC Markets.

CAR-T cell therapy is regarded as a cancer breakthrough. UPenn completed a study of 30 children and adults receiving a single injection of CAR-T cell therapy and 90% went into complete remission. This led to the U.S. FDA approving Kymriah®, a CAR-T cell therapy offered to leukemia patients for US$475,000 per dose.

Biocure Pharma is planning its Phase I & II clinical trials for its CAR-T cell therapy, BCP401 (leukemia), with the aim of launching to market in Korea by end 2022. Korea represents a US$2 billion p.a market for leukemia with substantial upside potential in Asia and Europe.

An investigator clinical trial was conducted at Beijing University Hospital in China using a CAR-T cell therapy provided by Pharos Vaccine, a research and development company of Biocure Pharma. The CAR-T program had a good response with a single dose.

The overall response rate was 55 of 56 subjects (98.21%) and complete remission in 53 of 56 (94.64%), superior to current FDA- approved CAR-T therapies. All patients were alive for 3 months.Complete Remission after BCP401

Biocure Pharma has also entered into a JV in Germany to progress its CAR-T cell therapy, BCP402 for lung, breast and pancreatic cancer. This, together with BCP401, provides numerous inflection points over the coming 24 months, as Biocure Pharma brings these therapies to market.

Financials

The Company in late July 2021 successfully completed a C$1.1M equity raise and is on track to achieve multiple key goals in 2021.

Announcements

Corporate Update and Financing

Read more

Closing of Financing

Read more

Dual listing in Germany and new contracts

Read more

Biocure Technology Inc. Announces Focus on its own CAR T-cell Therapy

Read more

Team

Sang Mok Lee

CEO & President, Director

Konstantin Lichtenwald

CFO, Director

Collin (Sang Goo) Kim

Director

Berkan Unal

Director

Danny Joh

Director

Jae Soo Shin

PHD

Heon Ju Lee

PHD

Hyun Soo Lee

PHD

    Thank you for your enquiry.
    We will be in touch as soon as possible.

    image

    Agripower

    Agriculture

    image

    Animoca Brands

    Online Gaming

    image

    Arbortech

    Industrials

    image

    Ausmincon Holdings Limited

    Mining

    Consulting

    image

    Blooms the Chemist

    Retail

    Pharmacy

    image

    Cannaponics Limited

    Health

    Agriculture

    image

    ConsenSys

    Software

    Blockchain

    image

    Crestone Holdings Limited

    Wealth Management

    image

    Digital Investment Group Limited

    Technology

    image

    Dona Blanca

    Pharmaceuticals

    Agriculture

    image

    Fort Street Real Estate Capital

    Property

    Fund

    image

    Hampton Hill Mining NL

    Metals & Mining